Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age–Period–Cohort Modelling

Ovarian cancer is the most lethal gynaecological cancer in very-high-human-development-index regions. Ovarian cancer incidence and mortality rates are estimated to globally rise by 2035, although incidence and mortality rates depend on the region and prevalence of the associated risk factors. The aim of this study is to assess changes in incidence and mortality of ovarian cancer in Catalonia by 2030. Bayesian autoregressive age–period–cohort models were used to predict the burden of OC incidence and mortality rates for the 2015–2030 period. Incidence and mortality rates of ovarian cancer are expected to decline in Catalonia by 2030 in women ≥ 45 years of age. A decrease in ovarian-cancer risk was observed with increasing year of birth, with a rebound in women born in the 1980s. A decrease in mortality was observed for the period of diagnosis and period of death. Nevertheless, ovarian-cancer mortality remains higher among older women compared to other age groups. Our study summarizes the most plausible scenario for ovarian-cancer changes in terms of incidence and mortality in Catalonia by 2030, which may be of interest from a public health perspective for policy implementation.

[1]  M. Parmar,et al.  Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2021, The Lancet.

[2]  W. Yue,et al.  International trends in ovarian cancer incidence from 1973 to 2012 , 2021, Archives of Gynecology and Obstetrics.

[3]  M. Pike,et al.  Association Between Breastfeeding and Ovarian Cancer Risk. , 2020, JAMA oncology.

[4]  F. Bray,et al.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence , 2020, International journal of cancer.

[5]  J. Marrugat,et al.  Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud , 2019, Revista Española de Cardiología.

[6]  J. Marrugat,et al.  Excess Weight in Spain: Current Situation, Projections for 2030, and Estimated Direct Extra Cost for the Spanish Health System. , 2019, Revista espanola de cardiologia.

[7]  Y. Hao,et al.  Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis , 2019, BMC Cancer.

[8]  R. Naumann,et al.  Ovarian cancer: screening and future directions , 2019, International Journal of Gynecologic Cancer.

[9]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[10]  M. Vilardell,et al.  Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly , 2018, Clinical and Translational Oncology.

[11]  S. Modesitt,et al.  Current and future role of genetic screening in gynecologic malignancies , 2017, American journal of obstetrics and gynecology.

[12]  F. Bray,et al.  International patterns and trends in ovarian cancer incidence, overall and by histologic subtype , 2017, International journal of cancer.

[13]  A. Green,et al.  Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future , 2017, Cancer Causes & Control.

[14]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[15]  M. Coleman,et al.  Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). , 2017, Gynecologic oncology.

[16]  D. Alberts,et al.  Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials , 2017, Clinical Cancer Research.

[17]  C. Navarro,et al.  Cancer incidence in Spain, 2015 , 2017, Clinical and Translational Oncology.

[18]  C. la Vecchia,et al.  Global trends and predictions in ovarian cancer mortality. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  N. Moitt,et al.  Cancer incidence and mortality projections in the UK until 2035 , 2016, British Journal of Cancer.

[20]  P. A. van den Brandt,et al.  Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Crous-Bou,et al.  Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic. , 2016, American journal of public health.

[22]  Yurii B. Shvetsov,et al.  Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. , 2016, International journal of epidemiology.

[23]  C. Garcés,et al.  Earlier menarcheal age in Spanish girls is related with an increase in body mass index between pre‐pubertal school age and adolescence , 2015, Pediatric obesity.

[24]  Bernd Holleczek,et al.  Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. , 2015, European journal of cancer.

[25]  V. Moreno,et al.  Hormonal contraception and postmenopausal hormone therapy in Spain: time trends and patterns of use , 2015, Menopause.

[26]  M. Coleman,et al.  Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. , 2012, Gynecologic oncology.

[27]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[28]  C. Navarro,et al.  Population-based cancer registries in Spain and their role in cancer control. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Borrás,et al.  RiskDiff: a web tool for the analysis of the difference due to risk and demographic factors for incidence or mortality data , 2009, BMC public health.

[30]  K. Reynolds,et al.  Global burden of obesity in 2005 and projections to 2030 , 2008, International Journal of Obesity.

[31]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[32]  J. L. Gutiérrez-Fisac,et al.  Increasing prevalence of overweight and obesity among Spanish adults, 1987–1997 , 2000, International Journal of Obesity.

[33]  J. Estève,et al.  Analysing the difference due to risk and demographic factors for incidence or mortality. , 2000, International journal of epidemiology.

[34]  THE WORLD OVARIAN CANCER COALITION ATLAS GLOBAL TRENDS IN INCIDENCE, MORTALITY AND SURVIVAL , 2018 .

[35]  I. Shah Fertility and contraception in Europe: the case of low fertility in southern Europe. , 1997, European journal of contraception & reproductive health care.

[36]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.